Description
The Practicing Oncologists Working Group is pleased to present a new series of Spotlight articles featuring highlights from the ESMO 2021 Congress.
Watch the presentations and make sure you keep up to date on the key practice changing outcomes from this year's annual meeting.
Produced by the Practising Oncologists Working Group
Featured abstracts
LBA5_PR - A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
Presenter: Karim Fizazi - Session: Presidential symposium 2
Abstract, slides and webcast
LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
Presenter: Gerhardt Attard - Session: Presidential symposium 2
Abstract, slides and webcast
LBA29 - Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
Presenter: Naveen Vasudev - Session: Proffered Paper session - Genitourinary tumours, non-prostate 2
Abstract, slides and webcast
LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study
Presenter: Neeraj Agarwal - Session: Proffered Paper session - Genitourinary tumours, prostate
Abstract, slides and webcast
